MX2019013714A - Metodos de tratamiento. - Google Patents

Metodos de tratamiento.

Info

Publication number
MX2019013714A
MX2019013714A MX2019013714A MX2019013714A MX2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A
Authority
MX
Mexico
Prior art keywords
posaconazole
treatment
substrate drug
patient
treated
Prior art date
Application number
MX2019013714A
Other languages
English (en)
Inventor
Christina Chow
Sundar Srinivasan
Original Assignee
Bow River LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bow River LLC filed Critical Bow River LLC
Publication of MX2019013714A publication Critical patent/MX2019013714A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona métodos para el tratamiento de un paciente con un fármaco de sustrato de CYP3A4 contraindicado para su administración concomitante con un inhibidor fuerte de CYP3A4, en donde el paciente se trata con múltiples dosis del posaconazol, interrumpe el tratamiento con el posaconazol, y entonces se trata con el fármaco de sustrato de CYP3A4. En algunas modalidades, el tratamiento con el fármaco de sustrato de CYP3A4 se retarda durante aproximadamente 2 a 21 días después de interrumpir el posaconazol. En algunas modalidades, el paciente se trata con, o se le prescribe, una dosis reducida del fármaco de sustrato de CYP3A4 durante aproximadamente 2 a 21 días después de interrumpir el posaconazol.
MX2019013714A 2017-05-16 2017-05-16 Metodos de tratamiento. MX2019013714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/596,585 US10376507B2 (en) 2017-05-16 2017-05-16 Method of treating a patient with a CYP3A4 substrate drug
PCT/US2017/032924 WO2018212764A1 (en) 2017-05-16 2017-05-16 Methods of treatment

Publications (1)

Publication Number Publication Date
MX2019013714A true MX2019013714A (es) 2020-07-14

Family

ID=64269934

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019013714A MX2019013714A (es) 2017-05-16 2017-05-16 Metodos de tratamiento.
MX2021000609A MX2021000609A (es) 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021000609A MX2021000609A (es) 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.

Country Status (14)

Country Link
US (4) US10376507B2 (es)
EP (3) EP4082546A1 (es)
JP (6) JP2020520380A (es)
KR (3) KR20210010663A (es)
AU (10) AU2017414697B2 (es)
CA (2) CA3062770A1 (es)
DK (1) DK3426250T3 (es)
ES (1) ES2912373T3 (es)
HR (1) HRP20220536T1 (es)
MX (3) MX2019013714A (es)
PL (1) PL3426250T3 (es)
SI (1) SI3426250T1 (es)
WO (2) WO2018212764A1 (es)
ZA (1) ZA202006746B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
SG11201906883SA (en) 2017-01-27 2019-08-27 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
PL3426250T3 (pl) * 2017-05-16 2022-08-08 Bow River LLC Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US11110098B2 (en) * 2017-06-07 2021-09-07 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION RELATED TO HUMAN IMMUNE DEFICIENCY VIRUS
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
AU2021412785A1 (en) * 2020-12-31 2023-06-22 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN112675175B (zh) * 2021-02-01 2022-11-01 天津济坤医药科技有限公司 布里格替尼在制备治疗特发性肺纤维化的药物中的应用
WO2023101441A1 (ko) * 2021-11-30 2023-06-08 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
WO2023141634A2 (en) * 2022-01-24 2023-07-27 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN117257994B (zh) * 2023-11-21 2024-03-01 北京大学人民医院 动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973970B2 (en) * 2000-08-09 2011-07-05 Ether Visuals Llc Preventing artifacts that may be produced when bottling PDL files converted from raster images
WO2007140299A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
KR20190067918A (ko) 2016-11-09 2019-06-17 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
PL3426250T3 (pl) 2017-05-16 2022-08-08 Bow River LLC Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs

Also Published As

Publication number Publication date
AU2020203606B2 (en) 2020-07-09
EP3716976A1 (en) 2020-10-07
AU2017414697B2 (en) 2020-03-05
AU2020250281B2 (en) 2022-07-28
US20190255043A1 (en) 2019-08-22
EP4082546A1 (en) 2022-11-02
EP3426250B1 (en) 2022-03-23
KR20200010320A (ko) 2020-01-30
JP2023174661A (ja) 2023-12-08
HRP20220536T1 (hr) 2022-06-10
MX2021000609A (es) 2021-06-23
KR20210010663A (ko) 2021-01-27
EP3426250A4 (en) 2020-05-06
AU2020203608B2 (en) 2020-07-09
AU2020250281A1 (en) 2020-11-05
WO2018212764A1 (en) 2018-11-22
WO2020018136A1 (en) 2020-01-23
JP7353343B2 (ja) 2023-09-29
MX2022013410A (es) 2022-11-14
JP2023021260A (ja) 2023-02-10
US20180333409A1 (en) 2018-11-22
CA3103793A1 (en) 2020-01-23
AU2017414697A1 (en) 2019-11-07
JP2022022264A (ja) 2022-02-03
AU2020203607B2 (en) 2020-07-09
EP3716976A4 (en) 2021-02-17
ZA202006746B (en) 2023-03-29
PL3426250T3 (pl) 2022-08-08
AU2022204806A1 (en) 2022-11-10
JP2021510681A (ja) 2021-04-30
AU2020202100A1 (en) 2020-04-09
AU2020202100B2 (en) 2020-07-02
CA3062770A1 (en) 2018-11-22
JP6984024B2 (ja) 2021-12-17
AU2020203606A1 (en) 2020-06-25
ES2912373T3 (es) 2022-05-25
AU2020203607A1 (en) 2020-06-25
JP2021059610A (ja) 2021-04-15
AU2018432858A1 (en) 2021-01-07
AU2020202266A1 (en) 2020-04-23
AU2020202266B2 (en) 2020-05-14
DK3426250T3 (da) 2022-05-16
US10376507B2 (en) 2019-08-13
AU2020203608A1 (en) 2020-06-25
JP2020520380A (ja) 2020-07-09
AU2022228153A1 (en) 2022-09-29
US20180333410A1 (en) 2018-11-22
SI3426250T1 (sl) 2022-09-30
KR20210045400A (ko) 2021-04-26
US20180333411A1 (en) 2018-11-22
EP3426250A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
MX2022013410A (es) Metodos de tratamiento.
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2019011221A (es) Terapia de combinacion para el tratamiento o prevencion de tumores.
MX2020010689A (es) Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
NZ755166A (en) Biofilm disrupting composition for use on chronic wounds
EP3795676A4 (en) APPLICATION OF B. FRAGILIS OR AKKERMANSIA MUCINIPHILA IN THE PREPARATION OF A MEDICINE INTENDED FOR PREVENTING OR TREATING A TUMOR
TW201613887A (en) Antiproliferative compounds and methods of use thereof
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
EA201992862A1 (ru) Назальные лекарственные формы дигидроэрготамина
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
EP3639829A4 (en) USE OF ISOVALERYLSPIRAMYCIN I, II AND / OR III IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND / OR PREVENTION OF A TUMOR, AND A MEDICINAL PRODUCT
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
NZ751972A (en) Treatment of prurigo nodularis
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.